Health care stocks were decreasing late Wednesday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) easing 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.4%.
In sector news, US Secretary of Health and Human Services Robert Kennedy Jr. is weighing a proposal for a key government vaccine advisory panel to scrutinize vaccines with aluminum ingredients, Bloomberg reported. A review could impact at least two dozen vaccines, the report said.
In corporate news, Zoetis (ZTS) shares were falling 3.7% after Stifel downgraded the stock to hold from buy and cut its price target to $160 from $165.
Gilead Sciences (GILD) shares added 0.3% after the drugmaker said the US Food and Drug Administration has approved its Yeztugo, its twice-yearly injectable for HIV prevention.
Caris Life Sciences (CAI) shares surged 23% in their Nasdaq debut Wednesday after the company priced its IPO of 23.5 million shares at $21 each.
Grail (GRAL) shares jumped 13% after the firm said it has seen better cancer detection results from an analysis of the first 25,578 participants in its Pathfinder 2 study, compared with the previous Pathfinder study.
Maia Biotechnology (MAIA) shares popped 9% after the company said it has signed a clinical master supply agreement with Roche
for hard-to-treat cancer therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.